QuantX Biosciences raised $85 million in a Series B led by Lilly and Sanofi Ventures to advance its China‑American pipeline focused on popular immunology targets. The financing will support R&D, candidate selection, and preclinical work aimed at small molecules or biologics targeting inflammatory and immune pathways. The round underscores continued VC interest from pharma corporate arms in biotech startups with dual‑market strategies and immunology-focused platforms. QuantX plans to deploy capital to accelerate programs and expand collaborations with industry partners.